CORDIS - EU research results

a user-friendly procedure that analyses genomic, clinical and demographic data to generate a personalized report with statistical analysis on the efficacy of antidepressants and their side effects

Project description

Introducing a platform for better treatment of depression

With the World Health Organization and European Commission recognising the impact of mental disorders, especially depression, on public health, solutions for better treatment or assistance are necessary. Both the WHO and EC have noted the importance of mental health services for treating mental disorders and administering efficient treatments, with personalised medicine proven as an important option. The EU-funded Predictix Antidepres project aims to introduce a platform that would offer medical practitioners better and up-to-date knowledge of each patient, allowing for better assessments and improved quality of life. They plan to achieve this by utilising their years of experience with genetics, data science and diseases of the central nervous system.


The World Health Organization recognizes mental disorders as one of the most significant public health challenges worldwide as measured by prevalence, burden of disease and disability , and depression as the world’s leading cause of disability. In EC and WHO action plans it is clearly requested that mental health services can be accessed without unfair financial barriers and that treatments are made available on criteria of both efficiency and financial fairness. In this framework personalised medicine is the fastest, most economic and optimized solution to the depression treatment problem. Indeed, the current push for a cost effective personalised medicine based on IT solution will also help with the commercialisation of our Predictix platform. The platform will allow medical practitioners to have up-to-date and accurate knowledge on each case and improve the care that patient receives, with an economic revenue too. Our solution allows for better delivery of available treatments – noted as a vital factor for increasing remission. TALIAZ was founded in 2012 by Dr. Dekel Taliaz and Oren Taliaz. Our mission is to set a new standard in personalized medicine improving quality of life for patients suffering from depression. Taliaz takes advantage of in-house expertise in genetics, data science and central nervous system related disease with the advancements in genetic sequencing and machine learning technologies, to develop leading personal medicine proprietary IP solutions for depression. Our future vision is to use Predictix™ also as a decision support tool for common health concerns such as ADHD and Anxiety. The SME Instrument project now perfectly fits our strategy and vision by enabling a fast finalisation of the platform development and by providing us the resources necessary to demonstrate the benefits of Predictix™ through an international clinical study.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
6801294 Tel-Aviv

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 71 429,00